

Synageva BioPharma Corp.

JOB DESCRIPTION

JOB TITLE	QC Research Scientist I
REPORTING RELATIONSHIP	Reports to Associate Director, Quality Control
DATE AVAILABLE	ASAP
LOCATION	Athens, GA
RESPONSIBILITIES	<p>Candidate will be responsible for the execution of accurate and compliant sample analyses following standard operating procedures in a cGLP/ cGMP laboratory to support manufacturing, product development and release of clinical materials. Specific responsibilities include, but are not limited to the following:</p> <ul style="list-style-type: none"> • Conducting routine and non-routine analysis of raw materials, in process, and finished formulations according to standard operating procedures • Compiles data for documentation of test procedures and prepares reports • Reviews QC data for compliance to procedures and specifications, and reports abnormalities • Authors technical reports • Performs assay method validations in accordance with applicable regulatory guidelines (FDA/ICH) • Author, revise and update standard operating procedures
REQUIREMENTS/ QUALIFICATIONS	<ul style="list-style-type: none"> • B.S. degree and at least 1 year of practical lab experience in relevant scientific discipline, chemistry, biochemistry, etc. <i>Candidates without a B.S. with more extensive practical lab experience will also be considered.</i> • Strong interpersonal skills and a high attention to detail are necessary. • Excellent time-management skills and must be able to demonstrate that they can creatively accomplish challenging tasks in a timely manner in a high energy/fast paced environment.
COMPANY DESCRIPTION	<p>Synageva BioPharma is a privately held biopharmaceutical company with headquarters, research and development facilities in Lexington, MA, and research and production facilities in Athens, GA. Synageva was formed to deliver orphan treatments for patients with rare diseases. Our lead program, SBC-102, an enzyme replacement therapy for LAL Deficiency, a serious and life threatening lysosomal storage disease, is in clinical development and has been granted orphan designation by the FDA. LAL Deficiency is a rare and devastating disease that leads to significant morbidity and mortality. Synageva has four additional orphan products in development. To ensure that these therapeutic candidates reach patients in need, Synageva has recruited a team with a proven record of discovery, development and commercial experience within rare diseases.</p> <p>Our work is based on creating value for patients and their healthcare providers, our shareholders and our employees. Our success brings new treatments to patients and providers. We are building a sustainable business and value for our shareholders because good medicine is good business. Our culture attracts and retains principle-minded individuals of integrity, drive, energy and passion.</p>